Cubist Systematic Strategies LLC Acquires New Shares in REGENXBIO Inc. (NASDAQ:RGNX)

Cubist Systematic Strategies LLC acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 361,313 shares of the biotechnology company's stock, valued at approximately $2,793,000. Cubist Systematic Strategies LLC owned about 0.73% of REGENXBIO as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the period. Balyasny Asset Management L.P. boosted its position in shares of REGENXBIO by 6.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company's stock valued at $9,176,000 after acquiring an additional 66,993 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of REGENXBIO by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock valued at $9,054,000 after acquiring an additional 21,234 shares during the period. Geode Capital Management LLC boosted its position in shares of REGENXBIO by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after acquiring an additional 5,574 shares during the period. Finally, Assenagon Asset Management S.A. boosted its position in shares of REGENXBIO by 53.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after acquiring an additional 296,700 shares during the period. Hedge funds and other institutional investors own 88.08% of the company's stock.

Insider Buying and Selling

In related news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the transaction, the director now directly owns 475,103 shares of the company's stock, valued at approximately $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.79% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RGNX shares. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. Chardan Capital reiterated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 target price for the company. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, March 7th. Finally, The Goldman Sachs Group dropped their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Stock Up 1.8%

Shares of NASDAQ:RGNX traded up $0.15 during midday trading on Wednesday, reaching $8.33. The company's stock had a trading volume of 1,188,144 shares, compared to its average volume of 863,289. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $16.85. The firm has a 50 day moving average of $7.43 and a 200-day moving average of $7.99. The firm has a market capitalization of $417.47 million, a P/E ratio of -1.66 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. On average, research analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.